292 related articles for article (PubMed ID: 29562821)
1. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.
Bajbouj K; Shafarin J; Hamad M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764470. PubMed ID: 29562821
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-induced disruption of intracellular iron metabolism leads to oxidative stress, membrane damage, and cell cycle arrest in MCF-7 cells.
Bajbouj K; Shafarin J; Abdalla MY; Ahmad IM; Hamad M
Tumour Biol; 2017 Oct; 39(10):1010428317726184. PubMed ID: 29022497
[TBL] [Abstract][Full Text] [Related]
3. Deferoxamine-induced increase in the intracellular iron levels in highly aggressive breast cancer cells leads to increased cell migration by enhancing TNF-α-dependent NF-κB signaling and TGF-β signaling.
Liu P; He K; Song H; Ma Z; Yin W; Xu LX
J Inorg Biochem; 2016 Jul; 160():40-8. PubMed ID: 27138103
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
5. DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage.
Greenshields AL; Power Coombs MR; Fernando W; Holbein BE; Hoskin DW
Biometals; 2019 Dec; 32(6):909-921. PubMed ID: 31624972
[TBL] [Abstract][Full Text] [Related]
6. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.
Ma S; Henson ES; Chen Y; Gibson SB
Cell Death Dis; 2016 Jul; 7(7):e2307. PubMed ID: 27441659
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells.
Power Coombs MR; Grant T; Greenshields AL; Arsenault DJ; Holbein BE; Hoskin DW
Exp Mol Pathol; 2015 Oct; 99(2):262-70. PubMed ID: 26210486
[TBL] [Abstract][Full Text] [Related]
9. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
10. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
11. The Role of Deferoxamine in Irradiated Breast Reconstruction: A Study of Oncologic Safety.
Lynn JV; Urlaub KM; Ranganathan K; Donneys A; Nelson NS; Subramanian C; Cohen MS; Buchman SR
Plast Reconstr Surg; 2019 Jun; 143(6):1666-1676. PubMed ID: 30907808
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
[TBL] [Abstract][Full Text] [Related]
13. Deferoxamine blocks death induced by glutathione depletion in PC 12 cells.
Chouraqui E; Leon A; Repesse Y; Prigent-Tessier A; Bouhallab S; Bougle D; Marie C; Duval D
Neurotoxicology; 2013 Jul; 37():221-30. PubMed ID: 23680049
[TBL] [Abstract][Full Text] [Related]
14. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.
Gharagozloo M; Khoshdel Z; Amirghofran Z
Eur J Pharmacol; 2008 Jul; 589(1-3):1-7. PubMed ID: 18619590
[TBL] [Abstract][Full Text] [Related]
15. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
16. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Kuban-Jankowska A; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Wozniak M
Anticancer Res; 2017 Sep; 37(9):4799-4806. PubMed ID: 28870898
[TBL] [Abstract][Full Text] [Related]
18. Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator.
Tanaka T; Muto N; Ido Y; Itoh N; Tanaka K
Biochim Biophys Acta; 1997 Jun; 1357(1):91-7. PubMed ID: 9202179
[TBL] [Abstract][Full Text] [Related]
19. Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.
Baschant U; Rauner M; Balaian E; Weidner H; Roetto A; Platzbecker U; Hofbauer LC
Haematologica; 2016 Dec; 101(12):1499-1507. PubMed ID: 27540134
[TBL] [Abstract][Full Text] [Related]
20. Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism.
Chen C; Wang S; Liu P
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
